2 available, 2 completed, 2 unknown, 1 terminated. .
Follow xCures: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases Alpha-Thalassemia, Beta-Thalassemia | Unknown | xCures | 1000 | 2024-06-10 | 2024-11-14 | |
| xPedite: A Study to Expedite DIPG and DMG Research Oncology, DIPG | Withdrawn | xCures | 2023-11-01 | 2026-11-02 | ||
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib Balversa - Bladder Cancer, Urothelial Carcinoma | Terminated | xCures | 2 | 2021-11-21 | 2022-12-22 | |
| Behavior, Environment And Treatments for Covid-19 Observation of patients with known, suspected, or at risk for COVID-19 infection - Coronavirus | Completed | xCures | 5000 | 2020-03-21 | 2022-07-14 | |
| A Patient-Centric Platform Trial for Precision Oncology Oncology | Unknown | xCures | 10000 | 2019-02-07 | 2023-02-03 | |
| Expanded Access to Gallium Maltolate (GaM) Gallium Maltolate - Glioblastoma, Refractory Glioblastoma | Available | Imaging Biometrics, LLC | 2026-06-08 | |||
| Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies Ulixertinib (BVD-523) - Pancreatic Cancer, Small Bowel Cancer | Available | xCures | 2026-06-04 |
Glioblastoma (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Cholangiocarcinoma (2) · Esophageal Neoplasms (2) · Melanoma (2) · Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Stomach Neoplasms (2) · Alzheimer Disease (1) · Amyloidosis (1) · Amyotrophic Lateral Sclerosis (1) · Anemia, Sickle Cell (1)
erdafitinib (1) · gallium maltolate (1) · ulixertinib (1)
United States (8)
Mark Shapiro (2) · Daniel J. George, MD (1) · Mark Shapiro, PhD (1) · Mark Stevens, Phd (1) · Rob Kimmerling, Phd (1)